FDA and industry have agreed to a draft commitment letter and proposed legislative language to reauthorize device-related FDA user fees.
The commitment, detailed in documents released by FDA last week, comes one month after the parties reached an agreement “in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?